Biological properties and functional determinants of the urotensin II receptor

Peptides

Volumn 29, Issue 5, 2008, Pages 691-699

  Proulx, Christophe D ^a   Holleran, Brian J ^a   Lavigne, Pierre ^a   Escher, Emanuel ^a   Guillemette, Gaétan ^a   Leduc, Richard ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

GPCR; Signal transduction; Structure; Urotensin II; Urotensin II receptor

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR FUNCTION; CONCENTRATION (PARAMETERS); DESENSITIZATION; HUMAN; INTERNALIZATION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 42049109932     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.10.027     Document Type: Review

References (110)

1. Abdelrahman A.M., and Pang C.C. Involvement of the nitric oxide/l-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 71 (2002) 819-825
2. Aiyar N., Johns D.G., Ao Z., Disa J., Behm D.J., Foley J.J., et al. Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). Biochem Pharmacol 69 (2005) 1069-1079
3. Alewijnse A.E., Timmerman H., Jacobs E.H., Smit M.J., Roovers E., Cotecchia S., et al. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol Pharmacol 57 (2000) 890-898
4. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
5. Ballesteros J.A., Jensen A.D., Liapakis G., Rasmussen S.G., Shi L., Gether U., et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276 (2001) 29171-29177
6. Ballesteros J.A., and Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors (1995), Academic Press, San Diego, CA
7. Barak L.S., Oakley R.H., Laporte S.A., and Caron M.G. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98 (2001) 93-98
8. Bergeron F., Leduc R., and Day R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J Mol Endocrinol 24 (2000) 1-22
9. Bern H.A., and Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 45 Suppl (1969) xi-xii
10. Bichet D.G. Nephrogenic diabetes insipidus. Am J Med 105 (1998) 431-442
11. Bihoreau C., Monnot C., Davies E., Teutsch B., Bernstein K.E., Corvol P., et al. Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. Proc Natl Acad Sci USA 90 (1993) 5133-5137
12. Boivin S., Guilhaudis L., Milazzo I., Oulyadi H., Davoust D., and Fournier A. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. Biochemistry 45 (2006) 5993-6002
13. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
14. Boucard A.A., Sauve S.S., Guillemette G., Escher E., and Leduc R. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. Biochem J 370 (2003) 829-838
15. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
16. Bousette N., Pottinger J., Ramli W., Ohlstein E.H., Dhanak D., Douglas S.A., et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
17. Bruchas M.R., Macey T.A., Lowe J.D., and Chavkin C. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281 (2006) 18081-18089
18. Buhl A.M., Johnson N.L., Dhanasekaran N., and Johnson G.L. G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J Biol Chem 270 (1995) 24631-24634
19. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 141-149
20. Castel H., Diallo M., Chatenet D., Leprince J., Desrues L., Schouft M.T., et al. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 99 (2006) 582-595
21. Charest P.G., Oligny-Longpre G., Bonin H., Azzi M., and Bouvier M. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19 (2007) 32-41
22. Chen Y., Zhao M., and Xia C. Effect of urotensin II on the airway smooth muscle cell proliferation and its mechanism. Zhonghua Yi Xue Za Zhi 80 (2000) 928-930
23. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
24. Chung D.A., Wade S.M., Fowler C.B., Woods D.D., Abada P.B., Mosberg H.I., et al. Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochem Biophys Res Commun 293 (2002) 1233-1241
25. Chung F.Z., Wang C.D., Potter P.C., Venter J.C., and Fraser C.M. Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. J Biol Chem 263 (1988) 4052-4055
26. Claing A., Laporte S.A., Caron M.G., and Lefkowitz R.J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66 (2002) 61-79
27. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
28. Dai H.Y., Ge Z.M., and Li Y.H. Effect of urotensin II on proliferative potential and phosphorylation of extracellular signal-regulated kinase 1/2 of adventitial fibroblasts from spontaneously hypertensive rat. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 (2006) 776-780
29. Demchyshyn L.L., Srikant C.B., Sunahara R.K., Kent G., Seeman P., Van Tol H.H., et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 43 (1993) 894-901
30. Deraet M., Rihakova L., Boucard A., Perodin J., Sauve S., Mathieu A.P., et al. Angiotensin II is bound to both receptors AT1 and AT2, parallel to the transmembrane domains and in an extended form. Can J Physiol Pharmacol 80 (2002) 418-425
31. Douglas S.A. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?. Curr Opin Pharmacol 3 (2003) 159-167
32. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
33. Douglas S.A., Naselsky D., Ao Z., Disa J., Herold C.L., Lynch F., et al. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 142 (2004) 921-932
34. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
35. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 (2002) 33-38
36. Dutt P., Kjoller L., Giel M., Hall A., and Toksoz D. Activated Galphaq family members induce Rho GTPase activation and Rho-dependent actin filament assembly. FEBS Lett 531 (2002) 565-569
37. Favre N., Fanelli F., Missotten M., Nichols A., Wilson J., di Tiani M., et al. The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry 44 (2005) 9990-10008
38. Feng W., and Song Z.H. Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochem Pharmacol 65 (2003) 1077-1085
39. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45 (2002) 1799-1805
40. Fromm C., Coso O.A., Montaner S., Xu N., and Gutkind J.S. The small GTP-binding protein Rho links G protein-coupled receptors and Galpha12 to the serum response element and to cellular transformation. Proc Natl Acad Sci USA 94 (1997) 10098-10103
41. Gaborik Z., Szaszak M., Szidonya L., Balla B., Paku S., Catt K.J., et al. Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol Pharmacol 59 (2001) 239-247
42. Gardiner S.M., March J.E., Kemp P.A., Davenport A.P., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132 (2001) 1625-1629
43. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Wang S., et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281 (2006) 10856-10864
44. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21 (2000) 90-113
45. Giebing G., Tolle M., Jurgensen J., Eichhorst J., Furkert J., Beyermann M., et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res 97 (2005) 707-715
46. Gohla A., Harhammer R., and Schultz G. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J Biol Chem 273 (1998) 4653-4659
47. Gohla A., Offermanns S., Wilkie T.M., and Schultz G. Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem 274 (1999) 17901-17907
48. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2006) 1527-1531
49. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 767-772
50. Hirshman C.A., and Emala C.W. Actin reorganization in airway smooth muscle cells involves Gq and Gi-2 activation of Rho. Am J Physiol 277 (1999) L653-L661
51. Holleran B.J., Beaulieu M.E., Proulx C.D., Lavigne P., Escher E., and Leduc R. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites. Biochem J 402 (2007) 51-61
52. Ishihata A., Ogaki T., Aita T., and Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523 (2005) 119-126
53. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402 (2000) R5-R7
54. Katoh H., Aoki J., Yamaguchi Y., Kitano Y., Ichikawa A., and Negishi M. Constitutively active Galpha12, Galpha13, and Galphaq induce Rho-dependent neurite retraction through different signaling pathways. J Biol Chem 273 (1998) 28700-28707
55. Labarrere P., Chatenet D., Leprince J., Marionneau C., Loirand G., Tonon M.C., et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 18 (2003) 77-88
56. Lacza Z., and Busija D. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 78 (2006) 2763-2766
57. Leclerc P.C., Auger-Messier M., Lanctot P.M., Escher E., Leduc R., and Guillemette G. A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. Endocrinology 143 (2002) 4702-4710
58. Lin L., Ding W.H., Jiang W., Zhang Y.G., Qi Y.F., Yuan W.J., et al. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 25 (2004) 1977-1984
59. Lohn M., Steioff K., Bleich M., Busch A.E., and Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol 507 (2005) 179-186
60. Luttrell L.M., Ferguson S.S., Daaka Y., Miller W.E., Maudsley S., Della Rocca G.J., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283 (1999) 655-661
61. Luttrell L.M., Roudabush F.L., Choy E.W., Miller W.E., Field M.E., Pierce K.L., et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 98 (2001) 2449-2454
62. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 (2004) 1767-1774
63. Marchese A., Heiber M., Nguyen T., Heng H.H., Saldivia V.R., Cheng R., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29 (1995) 335-344
64. Martin N.P., Lefkowitz R.J., and Shenoy S.K. Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem 278 (2003) 45954-45959
65. Matsusaka S., and Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 381-386
66. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
67. McLaughlin N.J., Banerjee A., Kelher M.R., Gamboni-Robertson F., Hamiel C., Sheppard F.R., et al. Platelet-activating factor-induced clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation. J Immunol 176 (2006) 7039-7050
68. Mhaouty-Kodja S., Barak L.S., Scheer A., Abuin L., Diviani D., Caron M.G., et al. Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features. Mol Pharmacol 55 (1999) 339-347
69. Mori M., and Fujino M. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides 25 (2004) 1815-1818
70. Mori M., Sugo T., Abe M., Shimomura Y., Kurihara M., Kitada C., et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265 (1999) 123-129
71. Neve K.A., Cox B.A., Henningsen R.A., Spanoyannis A., and Neve R.L. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol 39 (1991) 733-739
72. Nothacker H.P., and Clark S. From heart to mind. The urotensin II system and its evolving neurophysiological role. FEBS J 272 (2005) 5694-5702
73. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., and Caron M.G. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis. J Biol Chem 276 (2001) 19452-19460
74. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., and Barak L.S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275 (2000) 17201-17210
75. Onan D., Hannan R.D., and Thomas W.G. Urotensin II: the old kid in town. Trends Endocrinol Metab 15 (2004) 175-182
76. Onan D., Pipolo L., Yang E., Hannan R.D., and Thomas W.G. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 (2004) 2344-2354
77. Ong K.L., Lam K.S., and Cheung B.M. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19 (2005) 65-75
78. Pelletier G., Lihrmann I., Dubessy C., Luu-The V., Vaudry H., and Labrie F. Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. Neuroscience 132 (2005) 689-696
79. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Annu Rev Biochem 67 (1998) 653-692
80. Proulx C.D., Simaan M., Escher E., Laporte S.A., Guillemette G., and Leduc R. Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization. Biochem J 385 (2005) 115-123
81. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
82. Rossowski W.J., Cheng B.L., Taylor J.E., Datta R., and Coy D.H. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438 (2002) 159-170
83. Russell F.D., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 (2004) 673-681
84. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
85. Saetrum Opgaard O., Nothacker H., Ehlert F.J., and Krause D.N. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406 (2000) 265-271
86. Sagi S.A., Seasholtz T.M., Kobiashvili M., Wilson B.A., Toksoz D., and Brown J.H. Physical and functional interactions of Galphaq with Rho and its exchange factors. J Biol Chem 276 (2001) 15445-15452
87. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
88. Schwartz T.W., Frimurer T.M., Holst B., Rosenkilde M.M., and Elling C.E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46 (2006) 481-519
89. Segain J.P., Rolli-Derkinderen M., Gervois N., Raingeard de la Bletiere D., Loirand G., and Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179 (2007) 901-909
90. Shenoy S.K., and Lefkowitz R.J. Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE (2005) cm10
91. Slice L.W., Han S.K., and Simon M.I. Galphaq signaling is required for Rho-dependent transcriptional activation of the cyclooxygenase-2 promoter in fibroblasts. J Cell Physiol 194 (2003) 127-138
92. Smit M.J., Vischer H.F., Bakker R.A., Jongejan A., Timmerman H., Pardo L., et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47 (2007) 53-87
93. Somlyo A.P., and Somlyo A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83 (2003) 1325-1358
94. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
95. Strnad J., and Hadcock J.R. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Commun 216 (1995) 913-921
96. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
97. Tanowitz M., and Von Zastrow M. Ubiquitination-independent trafficking of G protein-coupled receptors to lysosomes. J Biol Chem 277 (2002) 50219-50222
98. Tasaki K., Hori M., Ozaki H., Karaki H., and Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci 94 (2004) 376-383
99. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
100. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
101. von Zastrow M., and Kobilka B.K. Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J Biol Chem 267 (1992) 3530-3538
102. Wang H., Mehta J.L., Chen K., Zhang X., and Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44 (2004) 577-581
103. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
104. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19 (2001) 2191-2196
105. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46 (2005) 738-744
106. Wyse B.D., Prior I.A., Qian H., Morrow I.C., Nixon S., Muncke C., et al. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 278 (2003) 23738-23746
107. Zhang A.Y., Chen Y.F., Zhang D.X., Yi F.X., Qi J., Andrade-Gordon P., et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol (2003)
108. Zhang J., Ferguson S.S., Barak L.S., Menard L., and Caron M.G. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem 271 (1996) 18302-18305
109. Ziltener P., Mueller C., Haenig B., Scherz M.W., and Nayler O. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J Recept Signal Trans Res 22 (2002) 155-168
110. Zou Y., Nagai R., and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508 (2001) 57-60